Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Theravance Biopharma, Inc.TBPH · Entity 5037 | PRESIDENT, TBIL | February 18, 2022 | February 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Theravance Biopharma, Inc.
Report date February 18, 2022 · Filed February 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 110,319 |
Reported balance
After 2022-02-18 transaction · row 1
1 source rowRow 1 · 2022-02-18 · Tax withholding · Disposed 8,369 · Balance 110,319 F1: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2022 Filed Feb 23, 2022 23:18 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 8,369 | $9.61 | $80,426.09 |
DisclosureSEC source: 0001415889-22-001693 · form4-02232022_030232.xml · nonDerivative · entry 1 BRADY ANN · CIK 0001767974 · PRESIDENT, TBIL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,319 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| November 19, 2021 Filed Nov 24, 2021 01:26 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 3,169 | $8.36 | $26,492.84 |
DisclosureSEC source: 0001415889-21-005472 · form4-11232021_051113.xml · nonDerivative · entry 1 BRADY ANN · CIK 0001767974 · PRESIDENT, TBIL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,688 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 22:50 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 3,169 | $14.05 | $44,524.45 |
DisclosureSEC source: 0001179110-21-008390 · edgar.xml · nonDerivative · entry 1 BRADY ANN · CIK 0001767974 · President, TBIL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,857 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| May 20, 2021 Filed May 24, 2021 22:07 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 3,169 | $17.80 | $56,408.20 |
DisclosureSEC source: 0001179110-21-005838 · edgar.xml · nonDerivative · entry 1 BRADY ANN · CIK 0001767974 · President, TBIL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,026 Read SEC document |
| February 20, 2021 Filed Feb 23, 2021 23:01 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 10,092 | $18.79 | $189,628.68 |
DisclosureSEC source: 0001179110-21-002152 · edgar.xml · nonDerivative · entry 1 BRADY ANN · CIK 0001767974 · President, TBIL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,195 Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:39 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001535 · edgar.xml · nonDerivative · entry 1 BRADY ANN · CIK 0001767974 · President, TBIL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,287 Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 23:13 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 2,292 | $17.21 | $39,445.32 |
DisclosureSEC source: 0001179110-20-011363 · edgar.xml · nonDerivative · entry 1 BRADY ANN · CIK 0001767974 · President, TBIL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,287 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:19 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 2,292 | $18.22 | $41,760.24 |
DisclosureSEC source: 0001179110-20-009259 · edgar.xml · nonDerivative · entry 1 BRADY ANN · CIK 0001767974 · President, TBIL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,579 Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:05 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 2,292 | $26.67 | $61,127.64 |
DisclosureSEC source: 0001179110-20-006521 · edgar.xml · nonDerivative · entry 1 BRADY ANN · CIK 0001767974 · President, TBIL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,871 Read SEC document |
| February 20, 2020 Filed Feb 25, 2020 00:05 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,948 | $25.90 | $154,053.20 |
DisclosureSEC source: 0001179110-20-002141 · edgar.xml · nonDerivative · entry 1 BRADY ANN · CIK 0001767974 · President, TBIL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,163 Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 23:55 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001196 · edgar.xml · nonDerivative · entry 1 BRADY ANN · CIK 0001767974 · President, TBIL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,111 Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 23:18 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 1,073 | $17.60 | $18,884.80 |
DisclosureSEC source: 0001179110-19-012011 · edgar.xml · nonDerivative · entry 1 BRADY ANN · CIK 0001767974 · President, TBIL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,111 Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 21:58 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 1,073 | $21.51 | $23,080.23 |
DisclosureSEC source: 0001179110-19-009783 · edgar.xml · nonDerivative · entry 1 BRADY ANN · CIK 0001767974 · President, TBIL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,184 Read SEC document |
| May 20, 2019 Filed May 22, 2019 22:03 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 1,073 | $19.84 | $21,288.32 |
DisclosureSEC source: 0001179110-19-006516 · edgar.xml · nonDerivative · entry 1 BRADY ANN · CIK 0001767974 · President, TBIL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,257 Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 23:11 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 3,023 | $27.00 | $81,621.00 |
DisclosureSEC source: 0001179110-19-002406 · edgar.xml · nonDerivative · entry 1 BRADY ANN · CIK 0001767974 · President, TBIL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,330 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.